Loading...
•
Sep 30, 2021
Veracyte Q3 2021 Earnings Report
Veracyte experienced strong revenue growth driven by the HalioDx acquisition and increased testing volume, despite the impact of the COVID-19 Delta variant.
Key Takeaways
Veracyte reported a 94% increase in total revenue to $60.4 million for Q3 2021, including $4.7 million from the recently acquired HalioDx. The company launched the Percepta Nasal Swab and Decipher Bladder tests and completed the acquisition of HalioDx, contributing to its transformation into a global cancer diagnostics leader.
Total revenue increased by 94% to $60.4 million, including $4.7 million from HalioDx.
Gross margin was 64%, which includes the impact of HalioDx.
Operating expenses, excluding the cost of revenue, increased by 123% to $55.4 million, including HalioDx expenses and acquisition-related costs.
Net loss increased by 243% to $14.1 million, including acquisition-related expenses and HalioDx net loss.
Revenue by Segment
Forward Guidance
Veracyte is updating its 2021 annual total revenue guidance to $210 million to $218 million, from the previous guidance range of $200 million to $208 million, with HalioDx expecting to contribute approximately $10 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...